A detailed history of Ubs Oconnor LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 300,000 shares of BDTX stock, worth $657,000. This represents 0.09% of its overall portfolio holdings.

Number of Shares
300,000
Holding current value
$657,000
% of portfolio
0.09%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.2 - $6.58 $894,600 - $1.4 Million
-213,000 Reduced 70.13%
90,706 $394,000
Q2 2024

Aug 14, 2024

BUY
$4.65 - $7.39 $217,182 - $345,157
46,706 Added 18.17%
303,706 $1.42 Million
Q1 2024

May 15, 2024

BUY
$2.67 - $5.74 $686,190 - $1.48 Million
257,000 New
257,000 $1.3 Million

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $79.6M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.